Login / Signup

Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population.

Kriangkrai TawinpraiTaweegrit SiripongboonsittiThachanun PorntharukchareonBothamai DechatesHarnphadungkit MonprachGaidganok SornsamdangKasiruck WittayasakKamonwan SoonklangNithi Mahanonda
Published in: Human vaccines & immunotherapeutics (2022)
A single dose of AZD1222 could elicit immune responses that did not decline within three months in Thai individuals. These data support the public health strategy of a delay between the prime and boost dose of AZD1222 of 4 to 12 weeks.
Keyphrases
  • immune response
  • public health
  • coronavirus disease
  • sars cov
  • dendritic cells
  • toll like receptor
  • electronic health record
  • big data
  • gestational age
  • machine learning